Vaccinex Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Vaccinex has been growing earnings at an average annual rate of 12.5%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 8.6% per year.
Belangrijke informatie
12.5%
Groei van de winst
49.9%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | -8.6% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | -4,987.9% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Vaccinex geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -18 | 7 | 0 |
| 31 Mar 24 | 0 | -19 | 7 | 0 |
| 31 Dec 23 | 1 | -20 | 7 | 0 |
| 30 Sep 23 | 1 | -22 | 7 | 3 |
| 30 Jun 23 | 1 | -22 | 7 | 0 |
| 31 Mar 23 | 1 | -20 | 6 | 0 |
| 31 Dec 22 | 0 | -20 | 6 | 0 |
| 30 Sep 22 | 0 | -19 | 6 | 10 |
| 30 Jun 22 | 0 | -20 | 6 | 0 |
| 31 Mar 22 | 0 | -20 | 6 | 0 |
| 31 Dec 21 | 1 | -22 | 6 | 0 |
| 30 Sep 21 | 1 | -24 | 7 | -17 |
| 30 Jun 21 | 1 | -28 | 7 | 0 |
| 31 Mar 21 | 1 | -28 | 7 | 0 |
| 31 Dec 20 | 1 | -29 | 7 | 0 |
| 30 Sep 20 | 1 | -29 | 7 | 17 |
| 30 Jun 20 | 0 | -28 | 7 | 0 |
| 31 Mar 20 | 0 | -30 | 7 | -7 |
| 31 Dec 19 | 1 | -32 | 7 | 0 |
| 30 Sep 19 | 1 | -34 | 6 | 7 |
| 30 Jun 19 | 1 | -33 | 6 | 12 |
| 31 Mar 19 | 1 | -31 | 5 | 25 |
| 31 Dec 18 | 1 | -30 | 5 | 22 |
| 30 Sep 18 | 1 | -24 | 4 | 20 |
| 30 Jun 18 | 0 | -24 | 4 | 19 |
| 31 Mar 18 | 0 | -23 | 5 | 17 |
| 31 Dec 17 | 0 | -22 | 4 | 17 |
| 31 Dec 16 | 0 | -26 | 4 | 16 |
Kwaliteitswinsten: VCNX is currently unprofitable.
Groeiende winstmarge: VCNX is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: VCNX is unprofitable, but has reduced losses over the past 5 years at a rate of 12.5% per year.
Versnelling van de groei: Unable to compare VCNX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: VCNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: VCNX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.